Top

Published in:

01-12-2011 | Epidemiology and Pathophysiology (Mone Zaidi and Jeffrey I. Mechanick, Section Editors)

Anti-Cancer Actions of Denosumab

Authors: Jameel Iqbal, Li Sun, Jeffrey I. Mechanick, Mone Zaidi

Published in: Current Osteoporosis Reports | Issue 4/2011

Abstract

Denosumab works by binding to and inhibiting receptor activator of nuclear factor-κB ligand (RANKL). Through this mechanism, it can inhibit any cause of bone destruction and thus shows great efficacy in high-turnover osteoporosis. The FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the effectiveness of denosumab as a therapy for menopausal bone loss, whereas several newer trials have found denosumab to have shown denosumab to be beneficial in preventing skeletal events from bone metastases. This review highlights the potential novel anti-cancer mechanisms of action of denosumab in mammary tumors.

Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.PubMedCrossRef

• Iqbal J, Sun L, Zaidi M. Denosumab for the treatment of osteoporosis. Curr Osteoporos Rep. 2010;8(4):163–7. This is our recent review on the benefits and downsides to denosumab therapy for osteoporosis treatment.PubMedCrossRef

• Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl J Med. 2009;361(8):756–65. This is one of the largest controlled clinical trials demonstrating the efficacy of denosumab in fracture prevention.PubMedCrossRef

West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol. 29(9):1095–1098.

van der Pluijm G. Cancer: breast cancer bone metastases: denosumab or zoledronic acid? Nat Rev Endocrinol. 2011;7(3):134–5.PubMedCrossRef

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.PubMedCrossRef

Park IH, Ro J, Nam BH, Kwon Y, Lee KS. Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases. BMC Cancer. 2009;9:154.PubMedCrossRef

Sun M, Iqbal J, Singh S, Sun L, Zaidi M. The crossover of bisphosphonates to cancer therapy. Ann N Y Acad Sci. 2010;1211:107–12.PubMedCrossRef

•• Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010;468(7320):98–102. Published together with the Gonzalez-Suarez et al. [10••] paper, details the more mild anti-cancer benefits of RANK deletion.PubMedCrossRef

10.

•• Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010;468(7320):103–7. Published together with the Schramek et al. [9••] paper, details the anti-cancer benefits of denosumab.PubMedCrossRef

11.

Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103(1):41–50.PubMedCrossRef

12.

Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002;20:795–823.PubMedCrossRef

13.

• Leibbrandt A, Penninger JM. Novel Functions of RANK(L) Signaling in the Immune System. Adv Exp Med Biol 2009;658:77–94. This is an outstanding review of the many underappreciated functions of RANKL in the immune system.CrossRef

14.

• Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 2008;1143:123–50. This is an excellent review of RANKL in bone metabolism.PubMedCrossRef

Title: Anti-Cancer Actions of Denosumab
Authors: Jameel Iqbal
Li Sun
Jeffrey I. Mechanick
Mone Zaidi
Publication date: 01-12-2011
Publisher: Current Science Inc.
Published in: Current Osteoporosis Reports / Issue 4/2011
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-011-0069-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anti-Cancer Actions of Denosumab

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Male Osteoporosis: Epidemiology and the Pathogenesis of Aging Bones

Rodent Models of Aging Bone: An Update

Vitamin D in the Persian Gulf: Integrative Physiology and Socioeconomic Factors

Bone, Inflammation, and Inflammatory Bowel Disease

Mechanical Loading: Bone Remodeling and Cartilage Maintenance

Rickets